🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. Parecoxib

    The First People's Hospital of Lianyungang

    Postoperative Pain Management, Pain Threshold, Shoulder Pain, Laparoscopies

    approved small molecule completed

    1 trial

  2. Parecoxib

    The First People's Hospital of Lianyungang

    Emergence Delirium

    approved small molecule active

    1 trial

  3. Pegylated liposomal doxorubicin

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  4. Pharmacotherapy

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule active

    1 trial

  5. Placebo used in this trial is a foodgrade, redried potato starch. It is a white powder with bland taste and free from objectionable odours. Insoluble in water with a temperature below 50 °C and most organic solvents, solution is slightly hazy. The product is intended for use in food., POTATO STARCH, SODIUM CHLORIDE, AMILORIDE

    Disc Medicine

    Autosomal Dominant Polycystic Kidney Disease

    approved small molecule active

    1 trial

  6. Pramipexole

    The First People's Hospital of Lianyungang

    Restless Legs Syndrome

    approved small molecule terminated

    1 trial

  7. Prothrombin Complex Concentrate, Human

    The First People's Hospital of Lianyungang

    Cardiac Surgical Procedures

    approved small molecule active

    1 trial

  8. Raltitrexed

    The First People's Hospital of Lianyungang

    Head and Neck Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  9. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  10. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  11. Recaticimab and Statin

    The First People's Hospital of Lianyungang

    Intracranial Atherosclerosis

    approved small molecule active

    1 trial

  12. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  13. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  14. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  15. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  16. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  17. Resveratrol

    The First People's Hospital of Lianyungang

    Pancreatitis, Acute

    approved small molecule active

    1 trial

  18. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  19. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

  20. Ropivacaine

    The First People's Hospital of Lianyungang

    Radius Fractures

    approved small molecule completed

    1 trial

  21. Ropivacaine

    The First People's Hospital of Lianyungang

    End Stage Renal Disease (ESRD)

    approved small molecule active

    1 trial

  22. Rosuvastatin

    The First People's Hospital of Lianyungang

    Hyperlipidemia

    approved small molecule active

    1 trial

  23. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial

  24. Ruxolitinib

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources